Welcome to our dedicated page for Weed news (Ticker: BUDZ), a resource for investors and traders seeking the latest updates and insights on Weed stock.
WEED Inc. reports developments tied to its cannabis and hemp bioresearch business, including cannabis-derived compounds, rare landrace strain genetics, and subsidiary activity in Arizona and international markets. Company updates have referenced HEMP BioSciences, industrial hemp licensing in Arizona, WEED Israel, and brand concepts spanning pharmaceutical, non-pharmaceutical, and consumer packaged goods categories.
News about BUDZ also covers portfolio and strategic matters, including the completed exit from the Colorado cannabis marketplace, real estate assets such as the Four Winds of Lake Erie property, cannabis policy developments, and management initiatives involving blockchain-enabled payment concepts and digital-asset infrastructure for the regulated cannabis and hemp sector.
Summary not available.
WEED, Inc. (OTCQB: BUDZ) announced the acquisition of Hempirical Genetics, LLC for 2 million shares valued at $.25 per share and $250,000 in cash over four years. This strategic move, described as a 'game changer', enhances WEED's cannabis genetics programs with over 30 new CBD and CBG strains, ultimately aimed at product development and clinical trials. Jeffery Miller, the previous owner, will lead development at HEMP BioSciences. The company aims to innovate in medical cannabis and build a pipeline of effective products while addressing legal and market uncertainties.
WEED, Inc. (OTCQB:BUDZ) announced that WEED Australia Ltd. will attend the United in Compassion Australian Medicinal Cannabis Symposium from May 20-22, 2022, in Queensland. The event aims to enhance understanding of cannabis applications in medicine. Key representatives include CEO Glenn E. Martin and Managing Director Patrick Brodnik. Discussions will focus on potential partnerships and the evolving legal framework for medicinal cannabis in Australia, as more patients seek access. The company aims to lead cannabis research and product development in the Asia-Pacific region.
WEED, Inc. (OTCQB:BUDZ) announced that its subsidiary, WEED Australia Ltd., has completed its financial statement requirements under ASIC rules, paving the way for a formal public offering anticipated in 2022 or 2023. The company is seeking strategic partnerships to bolster development, with a focus on cannabis-derived compounds for medical applications. CEO Glenn E. Martin will attend the 'United in Compassion' conference in May 2022 to explore collaborative opportunities. Despite positive developments, investors are cautioned about the significant legal risks associated with cannabis operations in the U.S.
WEED, Inc. (OTCQB:BUDZ) announces its strategic focus on expanding its trademark portfolio in the cannabis industry, aiming for enhanced brand recognition and shareholder value. The company holds a registered WEED® trademark and is pursuing additional registrations for PANAMA RED™ and ACAPULCO GOLD™ across various products and services. Through these efforts, WEED, Inc. plans to solidify its position as a leader in the cannabis sector while actively engaging in healthcare innovations for both humans and pets.
WEED, Inc. (OTCQB:BUDZ) announced plans to develop the Sugar Hill Golf Course in Westfield, NY into a luxury cannabis-friendly resort. Having recently completed a purchase of the property for ~$250,000, which was appraised at $1.9 million, they aim to establish a cannabis research division and luxury condos. Future ambitions include edibles and beverage research. The company intends to form a New York division to expand R&D programs and has budgeted $40 million for various initiatives, though no funds have been raised yet for the resort project.
WEED, Inc. (OTCQB:BUDZ) has acquired the Sugar Hill Golf Course for approximately $250,000, significantly lower than its 2019 appraisal value of $1.9 million. The company plans to develop a new division for infused beverages and edibles in New York, leveraging the property’s unlimited water extraction rights. Additionally, WEED aims to expand its R&D programs globally, focusing on cannabinoid strains and clinical trials. Despite ambitious plans, potential investors are cautioned about the significant legal risks associated with cannabis operations in the U.S.
WEED, Inc. (OTCQB:BUDZ) announced the formation of HEMP BioSciences Inc., aimed at expanding R&D in cannabis and hemp markets. CEO Glenn E. Martin emphasized the company's potential for growth, particularly through developing advanced CBD, CBN, and CBG strains. The new division will focus on both pharmaceutical and non-pharmaceutical products for global distribution. WEED's subsidiaries operate in several countries, including Australia and Israel, preparing for clinical trials aimed at enhancing women's health and treating PTSD.
WEED, Inc. (OTCQB:BUDZ) announced its upcoming presentation at Starlight Capital's virtual conference on March 25, 2021, where CEO Glenn E. Martin will unveil a new $40 million financing round under Regulation A. The company focuses on expanding its cannabis and hemp bioresearch initiatives globally. Martin highlighted opportunities for investors to participate in WEED's growth, emphasizing the company's plans post-COVID and its R&D partnerships in Australia, Israel, and Hong Kong. The offering aims to democratize investment in the cannabis market.
WEED, Inc. (BUDZ) has announced a new $40 million financing round under Regulation A, Tier 2, as qualified by the SEC. The company aims to expand its global R&D efforts and plans to acquire domestic and foreign cannabis-related assets. With subsidiaries in Australia, Israel, and Hong Kong, WEED is targeting growth in both pharmaceutical and non-pharmaceutical sectors. The offering consists of 40 million units at $1.00 each, including warrants for additional shares. The company emphasizes the potential benefit of increased public participation in the cannabis market.